- Report
- March 2025
- 138 Pages
Global
From €2246EUR$2,549USD£1,973GBP
€2643EUR$2,999USD£2,321GBP
- Report
- June 2025
- 320 Pages
Global
From €5243EUR$5,950USD£4,605GBP
- Report
- November 2025
- 185 Pages
Global
From €3965EUR$4,500USD£3,483GBP
- Report
- December 2025
- 383 Pages
Global
From €5155EUR$5,850USD£4,528GBP
- Report
- September 2025
- 250 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Report
- July 2025
- 150 Pages
Global
From €2644EUR$3,000USD£2,322GBP
€3305EUR$3,750USD£2,903GBP
- Report
- July 2025
- 85 Pages
Global
From €3500EUR$4,255USD£3,182GBP
- Report
- June 2025
- 100 Pages
United States
From €5243EUR$5,950USD£4,605GBP
- Report
- November 2025
- 192 Pages
Global
From €3124EUR$3,545USD£2,744GBP
€3471EUR$3,939USD£3,049GBP
- Report
- October 2025
- 90 Pages
Global
From €4274EUR$4,850USD£3,754GBP
- Report
- November 2025
- 250 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Report
- February 2025
- 200 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Report
- January 2025
- 175 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Report
- November 2024
- 265 Pages
Global
From €3679EUR$4,175USD£3,231GBP
- Report
- July 2023
- 152 Pages
Global
From €4098EUR$4,650USD£3,599GBP
- Report
- January 2024
- 66 Pages
Europe
From €2600EUR$2,950USD£2,283GBP
- Report
- March 2024
- 202 Pages
Global
From €4362EUR$4,950USD£3,831GBP
- Report
- February 2024
- 64 Pages
Asia Pacific
From €2600EUR$2,950USD£2,283GBP
- Report
- July 2024
- 154 Pages
Global
From €3183EUR$3,613USD£2,796GBP
€3745EUR$4,250USD£3,290GBP
- Report
- December 2022
- 246 Pages
Global
From €3172EUR$3,600USD£2,786GBP

Minimal Residual Disease (MRD) Testing is a type of In Vitro Diagnostics (IVD) used to detect the presence of cancer cells in a patient's body. It is used to monitor the effectiveness of cancer treatments and to detect the recurrence of cancer. MRD testing is typically performed on a sample of bone marrow or peripheral blood, and can detect cancer cells at levels as low as one in a million. It is used to detect the presence of cancer cells in patients with leukemia, lymphoma, and multiple myeloma.
MRD testing is a rapidly growing market, driven by the increasing prevalence of cancer and the need for more accurate and sensitive diagnostic tests. The development of new technologies, such as next-generation sequencing and flow cytometry, has enabled more accurate and sensitive MRD testing.
Companies in the MRD testing market include Abbott, Agilent Technologies, Bio-Rad Laboratories, Becton Dickinson, and Roche Diagnostics. Show Less Read more